Steric influence of salicylaldehyde-based Schiff base ligands on the formation of trans-[Re(PR3)2(Schiff base)]+ complexes

Zero-Carbon Emission Chemical Method to Remove Formaldehyde without Catalyst by Highly Porous Polymer Composites at Room Temperature

Herein, the fabrication of reduced graphene oxide (RGO)-templated polymer composites for chemical removal of gaseous formaldehyde under ambient conditions is presented. The chemical removal of formaldehyde is achieved by a nucleophilic addition reaction between formaldehyde and aminooxy groups on the polymer chain ends to form the oxime bonds with the only byproduct of H₂ O. RGO is essential since it not only has an ultralarge surface area but also can act as a perfect template for immobilizing pyrene-terminated and aminooxy-functionalized polymers via strong π-π stacking interactions, while melamine foam provides a three-dimensional skeleton for loading RGO/polymer composites to afford a porous 3D structure for efficient formaldehyde removal. Since the oxime bond can be cleaved into aminooxy group in acidic media, the RGO/polymer composite can be regenerated for repeatable usage, which shows an excellent performance of adsorbing 14 mg of formaldehyde by 100 mg of the polymer at ambient condition.

Crystal structure of catena-poly[diiodido-(μ2-1,5-dimethyl-2-phenyl-4-((pyridin-4- ylmethylene)amino)-1,2-dihydro-3H -pyrazol-3-one-κ2 N: O)zinc(II)], C17H16I2N4OZn

C17H16I2N4OZn, monoclinic, P21/n, a = 7.4827(5) Å, b = 14.9521(10) Å, c = 18.2838(13) Å, β = 99.251(1)°, V = 2019.0(2) Å3, Z = 4, R gt (F) = 0.0404, wR ref (F 2) = 0.787, T = 298 K.

Bifunctional chelators for radiorhenium: past, present and future outlook

Targeted radionuclide therapy (TRNT) is an ever-expanding field of nuclear medicine that provides a personalised approach to cancer treatment while limiting toxicity to normal tissues. It involves the radiolabelling of a biological targeting vector with an appropriate therapeutic radionuclide, often facilitated by the use of a bifunctional chelator (BFC) to stably link the two entities. The radioisotopes of rhenium, 186Re (t 1/2 = 90 h, 1.07 MeV β-, 137 keV γ (9%)) and 188Re (t 1/2 = 16.9 h, 2.12 MeV β-, 155 keV γ (15%)), are particularly attractive for radiotherapy because of their convenient and high-abundance β--particle emissions as well as their imageable γ-emissions and chemical similarity to technetium. As a transition metal element with multiple oxidation states and coordination numbers accessible for complexation, there is great opportunity available when it comes to developing novel BFCs for rhenium. The purpose of this review is to provide a recap on some of the past successes and failings, as well as show some more current efforts in the design of BFCs for 186/188Re. Future use of these radionuclides for radiotherapy depends on their cost-effective availability and this will also be discussed. Finally, bioconjugation strategies for radiolabelling biomolecules with 186/188Re will be touched upon.